Ask AI

Capsule Summaries

Share

Program Content

Activities

  • ASCENT03 Safety Analysis
    ASCENT-03: Safety Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Untreated Patients With Advanced TNBC Ineligible for PD-(L)1 Inhibitors
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • ASCENT07 Primary Results
    ASCENT-07: Primary Results From Sacituzumab Govitecan vs Chemotherapy as First Post-Endocrine Therapy in HR+/HER2- MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • PHERGuide
    PHERGuide: A Substudy of Translational Evaluation of ctDNA in Patients With HER2+ EBC Enrolled in PHERGain  
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • lidERA
    lidERA: Phase III Trial of Adjuvant Giredestrant vs Standard-of-Care Endocrine Therapy for ER+/HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • ELEVATE
    ELEVATE: Phase II Trial of Elacestrant + Everolimus or Abemaciclib in ER+/HER2- Locally Advanced or Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2025

  • ASCENT 04 Safety Analysis
    ASCENT-04: Safety Analysis of Phase III Trial of Pembrolizumab With Sacituzumab Govitecan or Chemotherapy in Previously Untreated PD-L1+ Metastatic TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2025

  • DATO Base Cohort C
    DATO-Base Cohort C: Datopotamab Deruxtecan in HER2-Negative Metastatic Breast Cancer With Leptomeningeal Disease
    Capsule Summary
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2025

  • PIK3CA Mutation Assays
    INAVO120: Evaluating PIK3CA Mutation Assays of Blood and Tissue From Phase III Trial of Palbociclib and Fulvestrant ± Inavolisib for Hormone Receptor–Positive/HER2-Negative ABC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2025

  • MONALEESA Response Markers
    MONALEESA Trials Pooled Analysis: Markers of Long-term Response to First-line Ribociclib + ET for HR-Positive/HER2-Negative Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2025

  • monarchE Nodal Status
    monarchE Subgroup Analysis by Nodal Status: Adjuvant Abemaciclib + ET for High-Risk, Node-Positive, HR+/HER2- Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2025

  • TBCRC 053 (P RAD)
    TBCRC-053 (P-RAD): Preoperative Chemotherapy and Pembrolizumab ± Low- or High-Dose Radiation in Node-Positive, HR+/HER2- BC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2025

  • DESTINY Breast11 Safety
    DESTINY-Breast11: Safety Analysis of Neoadjuvant T-DXd With or Without THP vs ddAC-THP in Patients With High-Risk HER2+ EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2025

  • HER2CLIMB-05
    HER2CLIMB-05: Tucatinib vs Placebo Added to Trastuzumab + Pertuzumab as First-line Maintenance Therapy for HER2+ MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • RT Plus Sacituzumab Govitecan in TNBC
    International Retrospective Safety Analysis for the Combination of Radiotherapy With Sacituzumab Govitecan in Advanced/Metastatic TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • AXSANA EUBREAST 3(R)
    AXSANA/EUBREAST 3(R): Primary Analysis of More vs Less Invasive Axillary Surgical Staging in Patients With Breast Cancer Downstaged From Clinically Node+ to Node- After Neoadjuvant Chemotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • SOLTI 2104 PremiÈRe
    SOLTI-2104-PremiÈRe: Phase II Trial of Elacestrant ± Triptorelin in Premenopausal Women With Estrogen Receptor (ER)–Positive/HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2025

  • SERENA-6 Update
    SERENA-6 Update: Camizestrant + CDK4/6 Inhibitor for Emergent ESR1m in Patients With HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2025

  • TROPION Breast02 Safety Analysis
    TROPION-Breast02: Safety Analyses of Dato-DXd vs Chemotherapy in Previously Untreated Patients With Advanced TNBC Not Suitable for Immunotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2025

  • evERA Subgroups
    evERA: Clinical and Biomarker Subgroup Analysis of Giredestrant + Everolimus in ER+/HER2− ABC Previously Treated with a CDK4/6 Inhibitor
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2025

  • PIKALO1
    PIKALO-1: Phase I/II Trial of PI3Kα Inhibitor LY4064809 for HR+, HER2-Negative PIK3CA-Mutant Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2025

  • NATALEE Update
    NATALEE: 5-Yr Distant DFS Across Key Subgroups With Ribociclib + NSAI in HR+/HER2- Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2025

  • EMBER-3 Update
    EMBER-3 Update: Imlunestrant ± Abemaciclib vs SoC ET in ER+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 23, 2025

  • DESTINY-Breast09
    DESTINY-Breast09: PROs With T-DXd + Pertuzumab vs THP as 1L Therapy in HER2+ Advanced or Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 23, 2025

  • ALTTO: AI vs Tam
    Exploratory Analysis From ALTTO (BIG 2-06) Study of Adjuvant AI or Tamoxifen in HR+/HER2+ EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 23, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.